Efficacy Observation of Fuzheng Sanjie Formula,Camrelizumab and Apatinib on Advanced Metastatic Esophageal Squamous Carcinoma with Syndrome of Zheng-deficiency-phlegm-stasis
Objective:To observe the clinical effect of Fuzheng Sanjie Recipe combined with camrelizumab and ap-atinib in the treatment of advanced metastatic esophageal squamous cell carcinoma with deficiency,phlegm and blood stasis type.Methods:60 patients with advanced metastatic esophageal squamous cell carcinoma who met the criteria were screened.The screened patients were randomly divided into an observation group and a control group at a ratio of 1:1 according to the random number table method,with 30 cases in each group.The observation group was given Fu-zheng Sanjie prescription combined with camrelizumab and apatinib;the control group was given camrelizumab and apatinib combined with immune targeted therapy.After 4 courses of treatment,the clinical efficacy of the observation group and the control group were compared.Results:After completing treatment,according to Response Evaluation Criteria in Solid Tumors(RECIST1.1),the disease control rates of patients who received combined traditional Chinese and Western medicine treatment and those who received only Western medicine treatment were 83.33%and 56.67%,respectively.By comparison,the disease control rates between the groups The difference was statistically significant(P<0.05).Compared with the 2 groups,the TCM syndrome score of the observation group improved more significantly(P<0.01),and the incidence of adverse reactions such as hypertension and liver and kidney damage was lower(P<0.05).And the KPS score of the observation group was significantly higher than before treatment(P<0.05).The patient self-assessment-subjective global assessment(PG-SGA)score and Hamilton(HAMD)score of the observation group were both higher than those before treatment.There was a decrease before,but no significant improvement was seen in the observation group(P>0.05).Conclusion:Fuzheng Sanjie Recipe,as an adjuvant therapy with camrelizumab and apat-inib,has good efficacy in the treatment of advanced metastatic esophageal squamous cell carcinoma with deficiency,phlegm and blood stasis type,and can effectively inhibit tumor growth and reduce the cost of targeted and immunother-apy.It can reduce side effects,reduce TCM symptom scores,improve patients'nutritional level and quality of life,and improve patients'mood.
国家科技期刊平台
NSTL
万方数据
